Fierce Biotech
VerifiedNewsletter (Digital)
Biopharma is a fast-growing world where big ideas come along daily. Our readers rely on Fierce Biotech for the latest news, analysis and data on drugs and the companies that make them. Fierce Biotech covers the biopharma waterfront, from drug development through the entire lifecycle—tracking regulatory approvals, payer negotiations, manufacturing, marketing, patent fights, government investigations and regulation, M&A deals and beyond. Our aim is to analyze the day's news, showing readers not only what they need to know, but why they need to know it. Beyond the daily, the Fierce Biotech team produces special reports that take stock of the industry's products and finances, and shed new light on industry trends. Source
Actions
Media Outlet details
| Scope | International, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Daily |
| Days Published | Mon, Tue, Wed, Thu, Fri |
Recent Articles
Search ArticlesBeyond the Hype: Turning NAMs into Actionable Evidence
There's a shift happening in how safety and efficacy are evaluated across drug development, chemicals, and beyond, and it's well past the theoretical stage. New Approach Methodologies (NAMs)—the broad family of in vitro systems and computational models—have matured into working tools. The value question has largely been settled. What organizations are grappling with now is harder and more practical: which tools to use, when to use them, and how to generate data that holds up when it matters most.
Biotech Giants and Investors Gather to Solve the Commercialisation Puzzle This May in Hong Kong
Biotech executives, investors, and R&D leaders all face the same burning question in 2026: How do we scale breakthroughs from the lab to the global market without getting stuck in commercial bottlenecks? The answer awaits this May at the Asia Summit on Global Health (ASGH), held 11-12 May in Hong Kong.
Asia Summit on Global Health (ASGH)
Welcome! In order to deliver a personalized and enhanced site navigation, we store information on how you use the site. We want you to know that we respect your privacy and your right to control how we collect and use your personal data. For more information, please see the Questex Privacy Policy Manage my cookie preferences
How ctDNA is redefining MRD monitoring in hematologic cancers
Liquid biopsy technologies, particularly circulating tumor DNA, or ctDNA, are changing how clinicians monitor hematologic malignancies. In this interview, Dr. Oksana Fabri explains how ctDNA provides a dynamic, systemwide view of disease burden that complements bone marrow biopsies and imaging while reducing the need for invasive procedures. Serial ctDNA measurements can detect molecular relapse months before clinical progression and are associated with progression-free and overall survival.
White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan
The White House is asking Congress for a $15.8 billion fiscal year 2027 discretionary budget cut for the Department of Health and Human Services, reflecting numerous program eliminations and other efficiencies it said will result from reorganizing subagencies. Friday’s requested $111.1 billion would be a 12.5% decrease from what Congress ultimately approved for the ongoing federal fiscal year.
Avoiding 11th hour surprises in clinical trials
In this episode of The Top Line, Olive McCormick joins host Chris Hayden to examine one of the most overlooked risks in clinical research: the last‑minute surprises that can derail a trial. McCormick, who has decades of experience in quality and regulatory leadership, warns that unexpected issues late in the process can jeopardize patient safety, compromise company credibility and stall hard‑won progress. She emphasizes that avoiding eleventh‑hour problems requires more than good intentions.
Almac Clinical Services
Proactive coordination is essential to protect patients, sponsors and trial integrity, especially as teams navigate the new UK Clinical Trial Regulation. Hear why alignment matters more than ever.
Stop asking for an AI strategy: 3 questions clinical leaders should ask instead
By Matthew Harrington, Global Head, Clinical Product, Syneos Health Artificial intelligence (AI) now features prominently in boardroom and executive discussions across the life sciences industry. The attention is understandable: AI has the potential to fundamentally reshape how companies discover, develop and deliver new therapies. Its effect on both business performance and patient outcomes will be substantial and far-reaching.
Why early developability assessment is a strategic necessity in modern antibody discovery
Monoclonal antibodies have become one of the most established and clinically successful therapeutic modalities, supported by decades of advances in discovery, engineering, and manufacturing. Many antibody programs progress efficiently from lead selection into development.
How physiology powers biotech innovation
Physiology explains how living systems function and remains the foundation of modern medicine. In this episode of The Top Line, Sue Bodine, president-elect of the American Physiological Society and a professor in the Aging and Metabolism Research Program at the Oklahoma Medical Research Foundation, discusses why physiology is essential to translating discovery into therapies, devices and digital health tools.